Cumberland (CPIX) earnings

CUMBERLAND PHARMACEUTICALS INC· Health Care

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Cumberland earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	8.8 $ million	−18.8% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	-35.9 %	−7.1 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-4.3 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$6.7 −6.69% · −$0.48

Last close Oct 19, 2026 · US · USD

Performance +94.8% 1Y

1Y: $3.44 on 17 Oct 2025 → $6.7. High $8.97 (26 Aug 2026), low $1.9 (17 Nov 2025).

Previous close: $7.18
52-week range: $1.9 – $8.97
One year: +88.20%

Overview

Symbol: CPIX
Sector: Health Care
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: −477% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	9	10	12	11	8	14	9	9
Expenses	11	12	10	4	10	15	12	3
Operating profit	-2	-2	1	-3	-2	-1	-3	-3
Operating margin	−18.6%	−17.6%	11.0%	−28.8%	−23.7%	−10.0%	−34.3%	−35.9%
Interest	0	0	0	0	0	0	0	0
Profit before tax	-2	-2	1	-3	-2	-1	-3	-3
Tax rate	−0.8%	2.9%	0.5%	−0.2%	−0.3%	−1.7%	−0.1%	−0.1%
Net profit	-2	-2	1	-1	-2	-1	-3	-4
EPS ($ per share)	-0.11	-0.14	0.08	-0.05	-0.13	-0.09	-0.22	-0.29

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	51	50	49	48	47	—	—	—
Reserves	5	1	-2	-6	-11	-17	-24	-27
Total liabilities	57	53	50	42	57	53	53	52
Fixed assets	1	1	1	0	0	0	0	0
Investments	8	0	—	—	—	—	—	—
Total assets	113	105	96	84	93	82	76	77

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	3	3	5	6	8	6	-1	5
Cash from investing	-28	2	-2	-1	-14	-0	0	-5
Cash from financing	7	-5	-7	-4	-2	-7	0	-7
Net cash flow	-17	0	-3	2	-7	-1	-0	-7
Capital expenditure	-0	-0	-0	-0	-0	-0	-0	-0
Free cash flow	3	3	5	6	8	6	-1	5

Source: Inve data · cash flow · to Dec 2025

Insider filings

211 filings between Oct 20, 2025 and Mar 18, 2026.

Open market

decisions to buy or sell

Nobody bought or sold CPIX on the open market in this window. The filings below are 6 awards, 1 tax withheld and 204 L filings.

Compensation

not trading decisions

6: Award — granted as compensation
1: Tax withheld — shares kept back by the company to cover tax

Latest filings (50)

Date	Insider	What	Shares	Value
Mar 18, 2026	Brown Martin S JR Director	Award	1,800	$5.0K
Mar 18, 2026	Krogulski Kenneth Director	Award	1,800	$5.0K
Mar 18, 2026	Krogulski Kenneth Director	Award	4,000	$11.2K
Mar 18, 2026	Jones James Director	Award	1,800	$5.0K
Mar 18, 2026	Young Caroline Director	Award	1,800	$5.0K
Mar 18, 2026	Galante Joseph C Director	Award	1,800	$5.0K
Mar 16, 2026	KAZIMI A J Chairman and CEO	Tax withheld	5,845	$17.9K
Dec 31, 2025	Young Caroline Director	Code L 10b5-1 plan	5	$20
Dec 31, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	62	$242
Dec 31, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	7	$27
Dec 31, 2025	Jones James Director	Code L 10b5-1 plan	7	$27
Dec 30, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	54	$213
Dec 30, 2025	Jones James Director	Code L 10b5-1 plan	8	$32
Dec 30, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	8	$32
Dec 30, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$8
Dec 29, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	8	$32
Dec 29, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$8
Dec 29, 2025	Jones James Director	Code L 10b5-1 plan	8	$32
Dec 29, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	54	$217
Dec 26, 2025	Jones James Director	Code L 10b5-1 plan	8	$34
Dec 26, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	54	$227
Dec 26, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	8	$34
Dec 26, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$8
Dec 24, 2025	Jones James Director	Code L 10b5-1 plan	8	$34
Dec 24, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	54	$230
Dec 24, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	8	$34
Dec 24, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$9
Dec 23, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	54	$223
Dec 23, 2025	Jones James Director	Code L 10b5-1 plan	8	$33
Dec 23, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	8	$33
Dec 23, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$8
Dec 22, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$9
Dec 22, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	50	$216
Dec 22, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	7	$30
Dec 22, 2025	Jones James Director	Code L 10b5-1 plan	7	$30
Dec 19, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	8	$34
Dec 19, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	52	$218
Dec 19, 2025	Jones James Director	Code L 10b5-1 plan	8	$34
Dec 19, 2025	Young Caroline Director	Code L 10b5-1 plan	2	$8
Dec 18, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	10	$42
Dec 18, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	67	$281
Dec 18, 2025	Jones James Director	Code L 10b5-1 plan	10	$42
Dec 18, 2025	Young Caroline Director	Code L 10b5-1 plan	3	$13
Dec 17, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	10	$37
Dec 17, 2025	Krogulski Kenneth Director	Code L 10b5-1 plan	67	$245
Dec 17, 2025	Young Caroline Director	Code L 10b5-1 plan	3	$11
Dec 17, 2025	Jones James Director	Code L 10b5-1 plan	10	$37
Dec 16, 2025	Young Caroline Director	Code L 10b5-1 plan	3	$10
Dec 16, 2025	Jones James Director	Code L 10b5-1 plan	14	$46
Dec 16, 2025	KAZIMI A J Chairman and CEO	Code L 10b5-1 plan	14	$46

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for CUMBERLAND PHARMACEUTICALS INC

Free account. Everything above stays public.

Write why you follow CUMBERLAND PHARMACEUTICALS INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading